Trends in Mid-sized European Licensing
On balance, do mid-sized European players receive more licensing dollars from out-licensing than they spend on in-licensing?
You may also be interested in...
Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.